{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:42Z","timestamp":1747181202796,"version":"3.40.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,26]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Prader-Willi syndrome (PWS) is a genetic disorder affecting multiple systems. Approximately one-quarter of PWS patients will develop diabetes. Given the uncontrolled hyperphagia and resultant severe obesity in these patients, their glycemic management poses a significant challenge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case report:<\/jats:title>\n            <jats:p>We present the clinical profile of a male patient diagnosed with both PWS and diabetes. Previous administration of the sodium-glucose co-transporter 2 (SGLT-2) inhibitor Canagliflozin resulted in improved glycemic control and weight management. But at the age of 25, the patient was hospitalized due to worsened glycemic control and the detection of ketonuria. After thorough examination and clinical observation, we discovered that the patient ketonuria was associated with enhanced lipid metabolism related to Canagliflozin. After excluding the risk of SGLT-2 inhibitor-induced euglycemic diabetic ketoacidosis, adjustments of the hypoglycemic regimen, building upon prior treatment, were recommended for the patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>It is important to note that among patients with both PWS and diabetes, the utilization of SGLT-2 inhibitors can lead to the emergence of ketonuria due to increased lipolysis. Therefore, any decision to discontinue SGLT-2 inhibitors should undergo thorough evaluation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000037096","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T03:01:28Z","timestamp":1706756488000},"page":"e37096","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Ketonuria in an adult with Prader-Willi syndrome and diabetes mellitus: A case report"],"prefix":"10.1097","volume":"103","author":[{"given":"Xiaoqing","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Beijing Hepingli Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayang","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular diseases, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huichai","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Hepingli Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Hepingli Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Hepingli Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1533-2809","authenticated-orcid":false,"given":"Zhongchen","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Hepingli Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","article-title":"Prader-Willi syndrome.","volume":"14","author":"Cassidy","year":"2012","journal-title":"Genet Med"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40618-015-0312-9","article-title":"Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings.","volume":"38","author":"Angulo","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"R3-20250503","first-page":"248","article-title":"Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study.","volume":"44","author":"Butler","year":"2002","journal-title":"Dev Med Child Neurol"},{"key":"R4-20250503","first-page":"397","article-title":"Age at diagnosis, body mass index and physical morbidity in children and adults with the Prader-Willi syndrome.","volume":"15","author":"Vogels","year":"2004","journal-title":"Genet Couns"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/ajmg.a.34171","article-title":"Physical health problems in adults with Prader-Willi syndrome.","volume":"155","author":"Sinnema","year":"2011","journal-title":"Am J Med Genet A"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11892-020-1284-5","article-title":"Update on diabetes mellitus and glucose metabolism alterations in Prader-Willi syndrome.","volume":"20","author":"Crin\u00f2","year":"2020","journal-title":"Curr Diab Rep"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"101418","DOI":"10.1016\/j.disamonth.2022.101418","article-title":"Diabetic ketoacidosis.","volume":"69","author":"Calimag","year":"2022","journal-title":"Dis Mon"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: a missed diagnosis.","volume":"12","author":"Nasa","year":"2021","journal-title":"World J Diabetes"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s42000-020-00256-0","article-title":"Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.","volume":"20","author":"Papanastasiou","year":"2021","journal-title":"Hormones (Athens)"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"7074868","DOI":"10.1155\/2018\/7074868","article-title":"Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis.","volume":"2018","author":"Yu","year":"2018","journal-title":"Int J Endocrinol"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.nutr.26.061505.111258","article-title":"Fuel metabolism in starvation.","volume":"26","author":"Cahill","year":"2006","journal-title":"Annu Rev Nutr"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice.","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"e11012","DOI":"10.1016\/j.heliyon.2022.e11012","article-title":"Beneficial effects of SGLT2 inhibitor on metabolic inflexibility and visceral fat amount in animal model of obese type 2 diabetes.","volume":"8","author":"Hara","year":"2022","journal-title":"Heliyon"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors.","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","article-title":"Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes.","volume":"15","author":"Laffel","year":"1999","journal-title":"Diabetes Metab Res Rev"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"102275","DOI":"10.1016\/j.dsx.2021.102275","article-title":"Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: a review of 72 cases over a 45-year period.","volume":"15","author":"Menghoum","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.3390\/nu13082590","article-title":"Plasma free fatty acid concentration as a modifiable risk factor for metabolic disease.","volume":"13","author":"Henderson","year":"2021","journal-title":"Nutrients"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1515\/jpem-2019-0389","article-title":"Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report.","volume":"33","author":"Candler","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s13300-018-0369-5","article-title":"Effectiveness of sodium-glucose cotransporter-2 inhibitor as an add-on drug to GLP-1 receptor agonists for glycemic control of a patient with Prader-Willi syndrome: a case report.","volume":"9","author":"Horikawa","year":"2018","journal-title":"Diabetes Ther"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1297\/cpe.29.81","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report.","volume":"29","author":"Sano","year":"2020","journal-title":"Clin Pediatr Endocrinol"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ijpo.12131","article-title":"Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.","volume":"12","author":"Salehi","year":"2017","journal-title":"Pediatr Obes"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:07:24Z","timestamp":1746317244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037096","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}